ENDEAVOR to change treatment for multiple myeloma?
Mené sur 929 patients atteints d'un myélome multiple récidivant ou réfractaire, cet essai randomisé multicentrique de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du carfilzomib et du bortézomib en combinaison avec la dexaméthasone
The advent of novel drugs, such as bortezomib and lenalidomide, has profoundly changed the therapeutic landscape for multiple myeloma, and classic regimens, such as melphalan plus prednisone, which were used for decades, are now treatments of the past. Combinations of dexamethasone with bortezomib or lenalidomide have become the backbone for treating patients with both newly diagnosed and relapsed multiple myeloma. Many attempts have been made to further improve the efficacy of bortezomib plus dexamethasone.
The Lancet Oncology , commentaire, 2014